P388 Immunological changes in IBD patients responding to low-dose naltrexone treatment
J Crohn's and Colitis
01 February 2012
LDN treatment was successful in part of the IBD patients not responding to other medication. Whether the
CD16+ CD62-L+ CD14 monocyte population is a direct target of the opioid growth factor opioid growth factor receptor signaling and therefore directly affected by the LDN treatment needs to be determined.